Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer

Rucaparib camsylate (CO-338, AG-014699, PF-01367338) is a potent PARP-1, PARP-2, and PARP-3 inhibitor. Phase I and II studies demonstrated clinical efficacy in both BRCA-mutated (inclusive of germline and somatic) ovarian tumors and ovarian tumors with homologous recombination deficiency (HRD) loss...

Descripción completa

Detalles Bibliográficos
Autores principales: Dockery, LE, Gunderson, CC, Moore, KN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488752/
https://www.ncbi.nlm.nih.gov/pubmed/28790837
http://dx.doi.org/10.2147/OTT.S114714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488752/
https://www.ncbi.nlm.nih.gov/pubmed/28790837
http://dx.doi.org/10.2147/OTT.S114714

Ejemplares similares